Small Dense Low Density Lipoprotein Predominance in Patients with Type 2 Diabetes Mellitus Using Mendelian Randomization

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Feb 8

PMID 38330008

Authors

Fengyi Zhang

Yufeng Zhang

Jiayi Zhang

Xin Wang

Yujie Li

Wenbo Wang

Affiliations

Soon will be listed here.

Abstract

Background: Patients with T2DM often suffer from CVD-related complications, significantly impacting morbidity and mortality rates. The upsurge in CVD prevalence among them is partly linked to sd LDL particles. Understanding the mechanisms behind elevated sd LDL levels is critical for preventing and managing cardiovascular complications in diabetes.

Methods: MR was employed to identify instrumental variables and establish causality, exploring underlying mechanisms.

Results: Notably, T2DM itself, insulin resistance, and fasting glucose seemingly do not directly impact sd LDL levels. Instead, the presence of T2DM or insulin resistance, leading to reduced HDL cholesterol or elevated TG levels, directly contributes to subsequent sd LDL increases, indicating a comprehensive mediating effect. While LDL cholesterol levels correlate positively with sd LDL, they appear unaffected by T2DM or insulin resistance. Importantly, hypertension induced by T2DM or insulin resistance exhibits a positive effect on sd LDL reversal. Unlike T2DM or insulin resistance, blood glucose levels show no significant impact on all processes.

Conclusions: It is hoped that these insights might influence the treatment of patients with diabetes and the management of blood parameters in clinical practice. Examining the effect of T2DM or insulin resistance on sd LDL within HDL cholesterol and triglycerides pathways might provide valuable insights for targeted cardiovascular treatments. Additionally, the study's exploration of the potential positive effects of elevated blood pressure on sd LDL reversal may introduce novel considerations for blood pressure management in patients with diabetes.

References

Laakso M, Lehto S, Penttila I, Pyorala K . Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993; 88(4 Pt 1):1421-30. DOI: 10.1161/01.cir.88.4.1421. View

DUNN F . Hyperlipidemia and diabetes. Med Clin North Am. 1982; 66(6):1347-60. DOI: 10.1016/s0025-7125(16)31368-2. View

Sanderson E, Davey Smith G, Windmeijer F, Bowden J . An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol. 2018; 48(3):713-727. PMC: 6734942. DOI: 10.1093/ije/dyy262. View

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157:107843. DOI: 10.1016/j.diabres.2019.107843. View

Li C, Wang D, Jiang Z, Gao Y, Sun L, Li R . Non-coding RNAs in diabetes mellitus and diabetic cardiovascular disease. Front Endocrinol (Lausanne). 2022; 13:961802. PMC: 9487522. DOI: 10.3389/fendo.2022.961802. View

Verbanck M, Chen C, Neale B, Do R . Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018; 50(5):693-698. PMC: 6083837. DOI: 10.1038/s41588-018-0099-7. View

ONeal D, Piers L, Iser D, Rowley K, Jenkins A, Best J . Australian Aboriginal people and Torres Strait Islanders have an atherogenic lipid profile that is characterised by low HDL-cholesterol level and small LDL particles. Atherosclerosis. 2008; 201(2):368-77. DOI: 10.1016/j.atherosclerosis.2008.03.022. View

Stern M, PATTERSON J, Haffner S, Hazuda H, Mitchell B . Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey. JAMA. 1989; 262(3):360-4. View

J Blake G, Otvos J, Rifai N, Ridker P . Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002; 106(15):1930-7. DOI: 10.1161/01.cir.0000033222.75187.b9. View

10.

Austin M, Breslow J, Hennekens C, Buring J, Willett W, Krauss R . Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988; 260(13):1917-21. View

11.

Davies N, Hill W, Anderson E, Sanderson E, Deary I, Davey Smith G . Multivariable two-sample Mendelian randomization estimates of the effects of intelligence and education on health. Elife. 2019; 8. PMC: 6748790. DOI: 10.7554/eLife.43990. View

12.

Edmunds E, Landray M, Li-Saw-Hee F, Hughes B, Beevers D, Lip G . Dyslipidaemia in patients with malignant-phase hypertension. QJM. 2001; 94(6):327-32. DOI: 10.1093/qjmed/94.6.327. View

13.

Krauss R . Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004; 27(6):1496-504. DOI: 10.2337/diacare.27.6.1496. View

14.

Ferrannini E, Cushman W . Diabetes and hypertension: the bad companions. Lancet. 2012; 380(9841):601-10. DOI: 10.1016/S0140-6736(12)60987-8. View

15.

Hirayama S, Miida T . Small dense LDL: An emerging risk factor for cardiovascular disease. Clin Chim Acta. 2012; 414:215-24. DOI: 10.1016/j.cca.2012.09.010. View

16.

Ai M, Otokozawa S, Asztalos B, Ito Y, Nakajima K, White C . Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 2010; 56(6):967-76. PMC: 3791882. DOI: 10.1373/clinchem.2009.137489. View

17.

Pearson E . Type 2 diabetes: a multifaceted disease. Diabetologia. 2019; 62(7):1107-1112. PMC: 6560016. DOI: 10.1007/s00125-019-4909-y. View

18.

Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A . Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017; 16(1):8. PMC: 5237208. DOI: 10.1186/s12933-016-0491-5. View

19.

Chen L, Yang H, Li H, He C, Yang L, Lv G . Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study. Hepatology. 2021; 75(4):785-796. PMC: 9300195. DOI: 10.1002/hep.32183. View

20.

Chen Q, Liu T, Zhou H, Peng H, Yan C . Risk of Fractures Associated with Dipeptidyl Peptidase-4 Inhibitor Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Ther. 2019; 10(5):1879-1892. PMC: 6778576. DOI: 10.1007/s13300-019-0668-5. View